Delivery Order SPE2DB22D2006-SPE2DB25FW4HJ
- Not listed
- The Defense Logistics Agency awarded a $7,046.76 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Monovisc 88 mg/4 ml syringes. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by September 17, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger indefinite delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,962.22 to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 mL syringes on September 5, 2025, with completion targeted for September 8, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Monovisc is a viscosupplement injection used to treat osteoarthritis pain, representing one of the specialized...
- The Defense Logistics Agency awarded a delivery order valued at $9,013.11 to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Monovisc 88 mg/4 ml syringes. The contract is a firm fixed-price delivery order with a completion date of August 6, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's capability to compete for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $14,829.77 to AmerisourceBergen Drug Corp for the supply of Monovisc 88 mg/4 mL syringes on September 24, 2025, with completion expected by September 25, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Monovisc is a viscosupplement injection used in orthopedic and rheumatological...
- The Defense Logistics Agency awarded a delivery order valued at $2,409.96 to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 ml syringes on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed price, non-set-aside contract represents a single delivery order fulfillment under AmerisourceBergen's larger indefinite delivery vehicle with DLA. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency awarded a $8,222.46 delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Monovisc 88 mg/4 mL syringes (4 mL quantity). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 15, 2025. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a $1,204.98 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Monovisc 88 mg/4 mL syringes. This is a non-set-aside contract with an ultimate completion date of September 23, 2025, and performance to be executed at the vendor's corporate office location in Conshohocken, Pennsylvania. As a child contract under a larger vehicle, this delivery order leverages AmerisourceBergen's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Monovisc 88 mg/4 mL syringes valued at $7,878.41. This firm fixed-price delivery order, with an ultimate completion date of September 9, 2025, represents a non-competitive, non-set-aside award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Monovisc is a viscosupplement treatment used to provide pain relief and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Monovisc 88 mg/4 mL syringes with a ceiling value of $6,256.75. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is due for completion by April 25, 2025, and will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location. As a major pharmaceutical distributor and healthcare solutions...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,551.43 on August 13, 2025, for the supply of Monovisc 88 mg/4 mL syringes. This firm fixed-price delivery order, which carries an ultimate completion date of August 14, 2025, represents a non-set-aside competitive award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Monovisc is a viscosupplement injection used primarily for osteoarthritis joint pain...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB25FW4HJDelivery Order
The Defense Logistics Agency awarded a $8,057.84 delivery order to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 mL syringes on September 23, 2025, with completion expected by September 24, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award to this major pharmaceutical distributor. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a critical vendor for federal medical procurement, AmerisourceBergen supplies pharmaceutical products and medical supplies to support military healthcare systems worldwide. Monovisc is a viscosupplement injection used in orthopedic and pain management applications, reflecting the company's role in providing specialized medical commodities across multiple therapeutic domains to the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.1k | 9/23/25 |